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Abstract: Ambrisentan is an endothelin receptor antagonist (ERA) that was recently approved 
for treatment of pulmonary arterial hypertension (PAH). Endothelin (ET) is a potent vasocon-
strictor with mitogenic, hypertrophic and pro-inﬂ  ammatory properties that is upregulated in 
pulmonary hypertensive diseases. The biologic effects of ET are mediated by 2 cell surface 
receptors termed ETA and ETB. ETA mediates the vasoconstrictor effect of ET on vascular 
smooth muscle, whereas ETB is expressed primarily on vascular endothelial cells where it 
induces nitric oxide synthesis and acts to clear ET from the circulation. Ambrisentan is the ﬁ  rst 
ETA selective ERA approved for use in the US. Recently published clinical trials in patients 
with PAH demonstrate improvement in functional capacity and pulmonary hemodynam-
ics similar to other ETA selective and non-selective ERAs. Its once daily dosing and lower 
incidence of serum aminotransferase elevation offer potential advantages over other ERAs, 
but further experience with this agent is needed to fully understand its long-term efﬁ  cacy and 
safety. This review discusses the endothelin family of proteins and receptors and their role in 
the pathophysiology of pulmonary hypertensive diseases. It also examines the development 
process, safety proﬁ  le and clinical trials that have resulted in ambrisentan being approved for 
treatment of PAH.
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Pulmonary hypertension
Pulmonary arterial hypertension (PAH) is a disease of the small pulmonary arteries 
that is characterized by vasoconstriction and vascular remodeling (Humbert et al 
2004b). In particular, hypertrophy and proliferation of pulmonary vascular smooth 
muscle results in thickening of the medial wall of mid sized pulmonary arteries and 
muscularization of more peripheral normally non-muscularized vessels (Tuder et al 
2001). Marked proliferation of endothelial cells in distal pulmonary arterials is also 
evident and in some areas causes near obliteration of the vascular lumen or tortuous 
remodeling with evidence of recanulized channels (plexiform lesions). This remodel-
ing of the pulmonary vascular bed substantially reduces the cross sectional area of the 
pulmonary vascular tree (Tuder et al 2007). At the same time, pulmonary vascular 
tone may be increased and the ability of the pulmonary circulation to dilate or recruit 
underutilized vessels in response to increased ﬂ  ow is reduced (Chan and Loscalzo 
2008). These changes result in a progressive increase in pulmonary vascular resistance 
(PVR) that increases right ventricular afterload, reduces exercise tolerance and in most 
cases results in right ventricular failure (Granton and Moric 2008).
Over the last 13 years, 6 drugs comprising 3 different drug classes have been 
approved for the treatment of PAH in the US (Table 1). All 6 drugs have been shown 
to decrease pulmonary arterial pressure, albeit to a minor degree, improve cardiac 
output and exercise capacity over a 3 to 4 month period and several have been shown 
to prolong survival compared to historical controls (Torres 2007; Gomberg-Maitland Drug Design, Development and Therapy 2008:2 266
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and Olschewski 2008). However, none of these drugs has 
been able to consistently reverse PAH or prevent disease 
progression and most are too recently developed to determine 
their long-term effect on survival. Furthermore, some of 
the more effective therapies are difﬁ  cult to use due to adverse 
effects or the need for continuous infusion or frequent 
inhalation (Gomberg-Maitland and Olschewski 2008). 
Hence, there remains a strong need to enhance or expand 
therapeutic options presently available to combat PAH.
The endothelins are a family of compounds composed of 
a similar 21 amino acid structure that have potent vasocon-
strictor properties and proliferative effects on pulmonary 
vascular smooth muscle and endothelial cells (Janakidevi 
et al 1992). In addition, endothelin (ET) has hypertrophic 
effects on cardiac myocytes (Schiffrin 2005) and impor-
tant proﬁ  brotic and pro-inﬂ  ammatory effects on a variety 
of cell types (Guarda et al 1993; Mullol et al 1996). Data 
suggesting a role of the endothelins in the pathophysiology 
of PAH include elevated circulating levels of endothelin-1 
(ET-1) in patients with PAH and increased expression of 
ET-1 in plexiform lesions (Matsui et al 2002) occluding 
the distal pulmonary arteries of PAH patients. Clinical 
studies have also shown a strong inverse relationship 
between plasma ET-1 levels and survival in patients with 
PAH (Franz et al 2008). As a consequence, there has been 
an intense interest in manipulation of endothelin signaling 
as therapeutic approach to PAH (Jeng et al 2002; Battistini 
et al 2006). Endothelin receptor antagonists (ERAs) have 
become an integral part of therapy for PAH (Jacobs et al 
2006) with 3 different drugs having been developed and 
approved for use (Table 1). Ambrisentan (LU 208075) 
an orally active diphenyl propionic acid derivative is the 
most recently developed ERA and received FDA approval 
in June, 2007.
The endothelins
In 1985, Hickey et al described an endothelium-derived con-
tractile factor that was subsequently isolated and sequenced 
by Yanagisawa et al from porcine aortic endothelial cell 
cultures in 1988 and named endothelin (Hickey et al 1985; 
Yanagisawa et al 1988). The discovery of endothelin was 
rapidly followed by the realization that its release, perhaps 
from a dysfunctional endothelium, could have a major role 
in the pathogenesis of numerous vascular diseases and that 
pharmacological manipulation of the ET system might 
provide important therapeutic advances (Haynes and Webb 
1992; Clozel and Roux 2000).
The endothelin (ETs) system consists of 3 identiﬁ  ed iso-
peptides, named endothelin-1, -2 and -3 (ET-1, ET-2, ET-3) 
possessing a similar 21 amino acid structure (Masaki et al 
1991). The most abundant and predominant isoform is ET-1. 
This peptide has unusually high and sustained vasoconstric-
tive activity (Clarke et al 1989). The initial observation that 
ET-1 vasoconstrictor activity was 10 times more potent than 
angiotensin II and 100 times more potent than norepinephrine 
quickly established its importance as a regulator of vascular 
tone (Yanigasawa et al 1988; Miyauchi et al 1990). Additional 
properties of ET-1 that implicate a signiﬁ  cant pathogenic role 
in vascular remodeling as well as the pathogenesis of PAH 
include mitogenic effects on endothelial cells, smooth muscle 
cells, ﬁ  broblasts, and pericytes, and a hypertrophic effect on 
cardiac myocytes (Luscher and Barton 2000).
Sequence analysis of the cDNA encoding ET revealed that 
biologically active ET-1 is synthesized in a 2-step proteolytic 
Table 1 Current medications approved for the treatment of pulmonary arterial hypertension
Generic name Trade name Drug class Administration routes Date approved
Epoprostenol Flolan Prostacyclin analogue Continuous IV infusion 1995
Treprostinil Remodulin Prostacyclin analogue Continuous IV or SQ infusion 2002 (SQ) 2004 (IV)
Iloprost Ventavis Prostacyclin analogue Nebulized inhalation 
6–9 times daily
2004
Bosentan Tracleer Non-selective endothelin
Receptor antagonist
Oral twice daily 2001
Ambrisentan Letairis Selective endothelin 
Receptor antagonist
Oral once daily 2007
Sitaxsentan Thelin Selective endothelin 
Receptor antagonist
Oral once daily 2006 (Europe, Canada)
Sildenaﬁ  l Revatio Phosphodiesterase 
type 5 inhibitor
Oral thrice daily 2005
Beraprost Prostacyclin analogue Oral 1 to 3 times per day 1994 (Japan)Drug Design, Development and Therapy 2008:2 267
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process from a large precursor peptide of 200 amino acid 
residues called preproET-1 (Inoue et al 1989). A neutral 
endopeptidase (a furin-like peptidase) cleaves preproET-1 to 
generate a smaller, but still mostly inactive precursor termed 
big-ET-1, that is further converted to ET-1 by endothelin-
converting enzymes (ECEs) (Hirata et al 1993; Laporte et al 
1993). This conversion is physiologically important because 
ET-1 is about 140-fold more potent a vasoconstrictor than 
big-ET-1. Identiﬁ  cation of the converting enzyme was chal-
lenging due to the small quantity of the enzyme contained in 
tissues (Takahashi et al 1993). The amino acid sequence of 
ECE was published in 1994 by 3 separate research groups 
(Schmidt et al 1994; Shimada et al 1994; Xu et al 1994). This 
enzyme was called ECE-1. In 1995, another isoform named 
ECE-2 was identiﬁ  ed (Opgenorth et al 1992). ECE-2 has a 
different pH sensitivity than ECE-1(Emoto and Yanagisawa 
1995). The existence of additional ECE isoforms was sus-
pected because high levels of ET-1 have been reported in 
ECE-1 and ECE-2 double-knockout mice (Yanagisawa et al 
2000). Now, 4 different human ECE-1 isoforms, derived 
from one gene by differential splicing, have been identiﬁ  ed 
and termed ECE-1a, ECE-1b, ECE-1c and ECE-1( Meidan   
et al 2005; Klipper et al 2006). These isoforms differ in their 
short N-terminal cytoplasmic domains and are present in 
different subcellular sites (Valdenaire et al 1999). ECE-1a is 
abundant in endothelial cells and resides within intracellular 
secretory vesicles and is constitutively transported to the cell 
surface (Russell and Davenport 1999). By contrast, ECE-1b 
is located intracellularly close to the trans-Golgi networks. 
The precise roles of the other isoforms are unknown.
ET-1 release via a constitutive pathway is regulated 
principally at the level of gene transcription. Synthesis 
is enhanced by protein kinase C- and phospholipase 
C-dependent pathways in response to physiological stimuli 
like low-shear stress, turbulent blood ﬂ  ow, angiotensin II, 
catecholamines, cardiotrophin-1, thrombin, growth factors, 
cytokines, free radicals, insulin, hypoxia, and shear stress 
(Emori et al 1991; Masaki et al 1991; Levin 1995; Love and 
McMurray 1996; Jougasaki et al 2002) . In contrast, the syn-
thesis of ET-1 is inhibited by high-shear stress, nitric oxide, 
natriuretic peptides, heparin, and prostaglandins (Boulanger 
and Luscher 1990; Hu et al 1992; Yokokawa et al 1993; Prins 
et al 1994; Gray and Webb 1996).
Endothelial cells release ET-1 abluminally and ET-1 acts 
on adjacent smooth muscle as a local autocrine or paracrine 
factor rather than as a hormone (Wagner et al 1992). Only a 
minor portion of released ET-1 is detected in the plasma, sug-
gesting that circulating levels of ET-1 represent an overﬂ  ow 
of endogenous tissue-bound ET-1 and thus do not allow for 
a true estimate of ET-1 activity. Despite these limitations, 
studies have established that plasma ET-1 levels are increased 
in PAH and that pulmonary expression and release of ET-1 
is increased in PAH (Stewart et al 1991). Interestingly, ET-1 
is also produced by other cells, including leukocytes, macro-
phages, smooth muscle cells, cardiomyocytes, and mesangial 
cells (Luscher and Barton 2000).
ET-1 binds to 2 heptahelical G-protein-coupled recep-
tors, named endothelin receptor-A (ETA) and endothelin 
receptor-B (ETB). The ETA receptor binds ET-1 and ET-2 
with greater afﬁ  nity than it does ET-3, whereas the ETB recep-
tor binds all three isoforms with equal afﬁ  nity (Simonson and 
Dunn 1990). Both receptors are distributed in various tissues 
and cells, but with different levels of expression. Receptor 
expression is altered in some disease states making the effect 
of receptor blockade difﬁ  cult to predict due to the wide range 
of functional expression within the ET system (Gregan et al 
2004). In response to ligand binding, ETA receptors induce 
vasoconstriction and cellular proliferation through the activa-
tion of phospholipase C and subsequent increase of inositol 
triphosphate, diacylglycerol, and intracellular calcium 
(Pollock et al 1995). Activation of ETB receptors on vascular 
smooth muscle causes vasoconstriction, whereas activation 
of ETB on endothelial cells stimulates the release of NO and 
prostacyclin, thus producing vasodilatory effects (Feger et al 
1997). However, the vasodilator effects of endothelial ETB 
activation are not enough to overcome the intense vasocon-
strictor effect of ETA activation and the overall effect of 
ET-1 in most vascular beds is one of intense vasoconstriction 
(Seo et al 1994).
The intracellular mechanisms by which ETs induce 
smooth muscle contraction have not been fully elucidated 
(Yanagisawa et al 2000). ET-1 causes a transient increase in 
the intracellular concentration of free Ca2+ ions, followed by 
a sustained elevation of free Ca2+ ions for 30 to 60 minutes 
resulting in prolonged contraction (Masaki et al 1999). The 
transient increase represents Ca2+ ions released from the 
intracellular pool of free Ca2+ via activation of phospho-
lipase C (PLC) (Miwa et al 1999). The sustained increase 
results from Ca2+ inﬂ  ux from the extracellular space. In the 
presence of physiological concentrations of ET-1, the Ca2+ 
inﬂ  ux is mediated by the activation of a non-selective cation 
channel(s) and a store-operated Ca2+ channel (SOCC).
In addition to its intense vasoconstrictor effect, ET-1 is a 
potent mitogen for a variety of cell types including vascular 
smooth muscle and cardiac myoctyes (Alberts et al 1994). 
The mitogenic effects of ET-1 are mediated by the activation Drug Design, Development and Therapy 2008:2 268
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of protein kinase C secondary to increases in diacylglycerol 
and intracellular calcium, which in turn stimulate the produc-
tion of cytokines and growth factors (Ohlstein et al 1992). 
ET-1 also activates leukocytes and promotes proliferation of 
endothelial cells, smooth muscle cells and astrocytes, mostly 
via ETA receptors. In contrast, activation of ETB can induce 
apoptosis, probably via its release of NO and/or prostacyclin, 
although the mechanisms responsible for this effect are not 
well understood (Verhaar et al 1998; Niwa et al 2000).
Clearance of ET-1 occurs primarily via binding to ETB, 
particularly in the vascular beds of the lungs and kidney. ET-1 
forms an insoluble bond with the ETB that is internalized and 
degraded (D’Orleans-Juste et al 2002). Clearance of ET-1 is 
rapid. The biological half–life following intravenous injec-
tion of radio-iodinated peptide in the rat is about 1 minute, 
while the pressor effects are maintained for nearly an hour 
(Sirvio et al 1990; Vierhapper et al 1990). In a single pass 
through the lungs, the human pulmonary circulation extracts 
roughly 50% of circulating ET-1 (Dupuis et al 1996). How-
ever, the arterio-venous ET-1 gradient is minimal due to a 
quantitatively similar degree of pulmonary ET-1 synthesis 
and release.
Endothelin and pulmonary 
hypertension
Circulating levels of ET-1 are elevated in PAH and ET-1 
expression is increased in the plexiform lesions obstructing 
the pre-capillary pulmonary microvasculature (Matsui 2002). 
Furthermore, the magnitude of overexpression of ET-1 has 
been shown to correlate with disease severity, cardiopul-
monary hemodynamics, and mortality (Cacoub et al 1993; 
Nootens et al 1995; Cacoub et al 1997; Galie et al 2004). 
ET-1 is a potent pulmonary vasoconstrictor and has anti-
apoptotic effects on endothelial cells and smooth muscle cells 
that may contribute to the pulmonary vascular abnormali-
ties seen in PAH (Budhiraja et al 2004). Although the link 
between the pulmonary arterial vasculopathy seen in PAH 
and excess synthesis of ET-1 is not fully understood at this 
time, the recognition that ET-1 contributes to the pathogen-
esis of PAH has led to the development of several ERAs that 
have demonstrated clinical efﬁ  cacy (Motte et al 2006).
The ERAs work by blocking the 2 receptors that medi-
ate the biologic functions of the endothelins. A strategi-
cally important question that arises is whether selective 
ETA receptor antagonism should result in better clinically 
efﬁ  cacy than blockade of both ETA and ETB (Langleben 
2007). In theory, selective ETA blockade would prevent 
the most salient vasoconstrictive and mitogenic effects of 
ET-1 while maintaining ETB mediated release of NO and 
prostacyclin and maximal clearance of circulating ET-1 
(Vatter and Seifert 2006). Indeed, Schroll et al found lower 
prostacyclin synthase expression in the pulmonary arteries 
of rats treated with bosentan than in those given ambrisentan 
(Schroll et al 2008). However, some studies suggest that dual 
blockade is necessary to achieve maximal vasodilation in 
pulmonary hypertension due to the vasoconstrictor effect of 
ETB on pulmonary vascular smooth muscle (Cacoub et al 
1993; MacLean et al 1995; McCulloch and MacLean 1995; 
Nootens et al 1995; Cacoub et al 1997; McCulloch et al 
1998; Galie et al 2004). Other studies suggest that selective 
ETA receptor antagonism may be more beneﬁ  cial (Dupuis 
2000). The potential advantage of a selective agent may 
reside in the relative importance of vasoconstriction medi-
ated by ETB. The in vitro effects of ETB activation varies 
with the cell type, the receptor-speciﬁ  c agonist used, and its 
concentration (Boss et al 2002). Previous studies support a 
much greater role for ETA than for ETB in the constrictive 
and proliferative responses of mesenchymal derived cells 
to ET-1 at concentrations similar to endogenous ET-1 levels 
seen in disease states (Shi-Wen et al 2004). However, animal 
studies have failed to demonstrate a signiﬁ  cant advantage 
to selective endothelial receptor antagonism. For example, 
in monocrotaline-induced PH, both the selective ETA 
blocker (darusentan 50 mg/kg/day) and the dual ETA and 
ETB antagonist (BSF-420627, 50 mg/kg/day) were effective 
in decreasing the severity of PH. Interestingly, decreased 
right ventricular hypertrophy and enhanced survival were 
seen only with the dual ETA and ETB antagonist, suggesting 
that non-selective (ETA/ETB) might be superior to selective 
ETA antagonism (Jasmin et al 2001). On the other hand 
selective ERA blockade has been shown to blunt monocro-
taline-induced increases in right ventricular ANP and beta 
myosin heavy chain mRNA, molecular markers for maladap-
tive cardiac hypertrophy (Miyauchi et al 2000). Whether or 
not the effects of ERAs on right ventricular hypertrophic 
responses in monocrotaline-induced PH are reproducible in 
patients with PAH remains to be established.
Two studies have demonstrated increased pulmonary 
vascular smooth muscle expression of ETB in human PAH 
(Bauer et al 2002; Davie et al 2002). ETB receptors are 
abundantly present in pulmonary vascular endothelial cells 
as well, particularly in the distal lung microvasculature 
(Davie et al 2002). However, the physiologic signiﬁ  cance 
of these ﬁ  ndings in PAH remains unclear. Increased expres-
sion of ETB in pulmonary vascular endothelial cells should 
enhance ET-1-mediated release of NO and prostacyclin Drug Design, Development and Therapy 2008:2 269
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while improving clearance of ET-1 from the circulation 
(de Nucci et al 1988), whereas increased expression of 
ETB in pulmonary vascular smooth muscle cells would be 
expected to increase vasoconstriction and perhaps worsen 
medial thickening. Langleben et al found that most PAH 
patients have intact endothelial ETB-mediated clearance, 
despite a reduced microvascular surface area from vascular 
remodeling, suggesting that increased expression of ETB is 
needed to maintain normal endothelin clearance (Langleben 
et al 2006).
The ET receptor selectivity of presently available ERAs 
has been the topic of considerable debate. An ETA:ETB bind-
ing ratio  2000:1 in a standard in vitro assay is considered 
selective for ETA ( Sitbon et al 2004; Galie et al 2006). How-
ever, endothelin receptor binding speciﬁ  city varies widely 
depending on the experimental system used (Black et al 
2003). The degree of selectivity also relates to the concen-
tration of the antagonist, so even a selective antagonist will 
become relatively less selective at very high doses. Given the 
wide variation in values obtained using different experimen-
tal systems, the deﬁ  nition of receptor selectivity is somewhat 
arbitrary. However, for the sake of clinical practice, most 
investigators consider bosentan to be a non-selective ERA 
(Clozel 2003) having only slightly greater afﬁ  nity for ETA 
than ETB (approximately 4–100:1) (Morimoto et al 2001), 
whereas sitaxsentan and ambrisentan are considered selective 
ETA antagonists demonstrating far greater afﬁ  nity for ETA 
than for ETB by 2 to 3 orders of magnitude.
Development of ambrisentan
Several different structural classes of ERAs, ranging from 
peptidic- and peptidomimetic structures to small organic mol-
ecules suitable for oral administration have been discovered 
within the last decade. Bosentan, one of the ﬁ  rst orally active 
compounds with an antagonistic effect of ETA and ETB, is a 
tetra-substituted pyrimidine (Clozel et al 1994). It was the 
ﬁ  rst ERA approved for treatment of PAH in Europe and the 
US and its therapeutic efﬁ  cacy has been demonstrated in 
several randomized, double-blind, placebo-controlled studies 
(Rich and McLaughlin 2003; Liu and Chen 2006).
The initial 3,3-diphenyl propionic acid based ERAs 
from BASF/Knoll were discovered by screening of BASF’s 
chemical library for compounds that bind to recombinant 
human ETA receptor. Screening of those compounds, initially 
designed as herbicides, led to the discovery of a novel 
series of potent ETA-selective antagonists. The attempts 
to simplify the structure and enhance the binding activity 
of these antagonists gave rise to LU-135252 (darusentan) 
the active enantiomer of racemic LU-127043. Darusentan 
is selective for ETA; its Ki-values for the displacement 
of  [125I]ET-1 in human receptors expressed in the Chinese 
hamster ovary (CHO) cells are 1.5 nM for ETA- and 184 nM 
for ETB.(Riechers et al 1996; Prie et al 1997). Slight modiﬁ  ca-
tion of the structure of darusentan led to a similar compound, 
LU 208075, which was subsequently named ambrisentan 
(Billman 2002; Bolli et al 2004).
As discussed earlier, selectivity of an ERA is usually 
determined by its ability to bind ETA and ETB in a standard 
in vitro assay. As with other ERA, the selectivity of 
abmbrisentan for ETA has varied considerably depending on 
the dose and model used. For example, the afﬁ  nity of ambris-
entan was approximately 1 nM for ETA and 195 nM for ETB 
in human ET-receptors expressed in CHO cells (Riechers 
et al 1996), but only 54-fold higher in intact CHO cell lines 
expressing recombinant human ET-receptors (Bolli et al 
2004), 77-fold higher in canine cells (Ki-values: 0.63 nM 
ETA; 48.7 nM ETB) (Amberg et al 1999) and 29-fold higher 
in rat tracheal and aortic smooth muscle (Bolli et al 2004). 
These values are similar to those obtained by Vatter et al 
who found that the selectivity of ambrisentan for ETA in 
ET-1-induced contraction of cerebral arteries of rats was 
approximately one logarithmic unit greater than ETB (Vatter 
et al 2003). In contrast, studies using human ventricular 
myocyte-derived ETA and ETB receptors have shown that the 
Ki (dissociation constant for the inhibitor) of ambrisentan for 
ETA is, approximately 0.011 nM, more than 400-fold higher 
than for ETB (Greene 2006). At therapeutically relevant 
plasma concentrations in PAH, ambrisentan has higher recep-
tor occupancy with ETA ( 90%), than ETB ( 10%). Despite 
this, the reported selectivity of ambrisentan for ETA of only 
77/1 (Amberg et al 1999), is somewhat less than the gener-
ally accepted ratio needed for the qualiﬁ  cation as a selective 
ETA receptor antagonist. Furthermore, signiﬁ  cant increases in 
plasma ET-1 levels have been reported 2 hours after ingestion 
of ambrisentan suggesting at least some functional antago-
nism of ETB in vivo (FDA 2007; Opitz et al 2008).
Pharmacokinetics of ambrisentan
Ambrisentan, differs from bosentan and sitaxsentan in that it 
is a propanoic acid-class molecule rather than a sulfonamide-
class agent. The chemical composition of ambrisentan, also 
known as LU 208075 or BSF 208075, is C22 H22N2O4, and 
its molecular weight is 378.4 g/mol (Rubin et al) (Figure 1). 
Ambrisentan is rapidly absorbed into the systemic circula-
tion after oral administration, with high bioavailability of 
about 90% of the ingested dose and a duration of action Drug Design, Development and Therapy 2008:2 270
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longer than 6 hours (Amberg et al 1999; Hopfner 1999). 
In a Phase II trial of patients suffering from PAH, plasma 
levels of ambrisentan reached Cmax between 1.7 and 3.3 hours 
after oral administration (Galie et al 2005a). The pharma-
cokinetics of ambrisentan are dose-linear over a range of 1 
to 100 mg and are not affected by food intake. Steady-state 
is achieved after 3 to 4 days of once-daily oral dosing, and 
the pharmacokinetics of multiple doses (ie, steady-state 
ambrisentan) are consistent with observations after a single 
dose. The steady-state elimination half-life of ambrisentan 
in PAH patients is approximately 15 hours for the 5 mg 
dose and ranges from 13.6 to 16.5 hours in normal subjects, 
providing the rationale for once-daily dosing.
Ambrisentan undergoes little metabolism and is excreted 
mostly unchanged in bile. Following oral administration 
of a radio-labeled dose in preclinical studies, ambrisentan 
was detected primarily in the liver and plasma 2 to 4 hours 
after administration. The majority of the radio-labeled dose 
was recovered in the feces as unchanged or glucuronide-
conjugated drug (FDA 2007; Cheng 2008).
Clinical efﬁ  cacy
Clinical trials with ambrisentan have been performed since 
2001, but the initial Phase II trials conducted in patients 
with hypertension, renal failure, cardiac failure, or car-
diovascular diseases were not reported in the literature. 
Clinical data from the Phase II dose ranging trial in 
patients with PAH were published in 2005 (Galie et al 
2005a). In addition, the results of 2 parallel, Phase III, 
randomized controlled trials with ambrisentan have 
recently been published in one paper (Galie et al 2008) 
and a open-label study of patients treated with ambrisentan 
after developing elevated liver function tests (LFTs) 
while taking bosentan has been published in abstract form 
(McGoon et al 2006).
In the Phase 2, double-blind, non-controlled dose-ranging 
study, 64 patients with idiopathic PAH or PAH associated 
with connective tissue disease, anorexigen use, or HIV were 
randomized to receive oral ambrisentan 1, 2.5, 5, or 10 mg 
once-daily for 12 weeks, followed by a 12-week open-label 
treatment period (Galie et al 2005a) . All patients were WHO 
functional class II or III at baseline. Six patients discon-
tinued the study prior to the 12-week period. The last data 
obtained from these 6 patients were carried forward to the 
12 week time point. Fifty-six of the remaining 58 patients 
were enrolled in an additional 12-week open label study. 
The primary endpoint was the change from baseline in 
6-minute walking distance (6MWD) after 12 weeks. Sec-
ondary endpoints included change from baseline in WHO 
functional class, Borg dyspnea index (BDI), subject global 
assessment, and cardiopulmonary hemodynamics. When data 
from all 4 dose groups were combined the mean increase in 
6MWD after 12 weeks of therapy was 36.1 m (p   0.0001). 
A similar improvement from baseline 6MWD was observed 
for each dose of ambrisentan tested: +33.9 (p = 0.0029), +37.1 
(p = 0.0004), +38.1 (p = 0.0112), and +35.1 (p = 0.0080) m 
for the 1-, 2.5-, 5-, and 10-mg-dose groups, respectively, 
suggesting no dose-response relationship. Subgroup analyses 
indicate that the 6MWD increased in patients with IPAH 
(+39.9 m, p   0.0001) as well as in patients with PAH 
due to other etiologies (+30.2 m, for PAH associated with 
connective tissue disease, anorexigen use, and HIV combined 
p = 0.0026). The magnitude of increase in 6MWD was com-
parable in WHO functional class II and III. Exercise capacity 
continued to increase throughout the 12-week open-label 
period, reaching a maximum improvement from baseline of 
54 m at week 24.
Improvements in WHO functional class were observed 
for all dose groups. Eighteen (36%) patients improved 
by 1 or more WHO functional classes, whereas only 
2 (3.4%) patients deteriorated in WHO functional class. By 
week 12, clinical worsening of PAH was observed in 13 of 
64 patients (20.3%). In 6 (46.2%) of the 13 patients clinical 
worsening of PAH was deﬁ  ned as an increase in the dose of 
diuretic. During the open-label extension period, there were 
8 patients in whom clinical worsening developed and 5 were 
attributable to an increased dose of diuretic. At week 
12, there was a mean improvement from baseline indicated 








Figure 1 Molecular structure of ambrisentan.Drug Design, Development and Therapy 2008:2 271
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0.9 ± 0.4, 1.0 ± 0.6, and 1.0 ± 0.6 for the 1-, 2.5-, 5-, and 
10-mg-dose groups, respectively. The Borg dyspnea index 
score at baseline for all dose groups combined was 4.0 ± 0.3, 
which improved –0.9 ± 0.3 (p = 0.0015) at week 12 and 
was maintained through week 24 (−1.3 ± 0.3, p   0.0001). 
Signiﬁ  cant improvements were also observed in quality of 
life, as measured by a subject global assessment (11.3 ± 2.4 
and 12.1 ± 2.7 mm at weeks 12 and 24, respectively; 
p   0.0001). A subgroup of 29 patients (8–9 patients for the 
1, 2.5, and 5 mg doses and 3 patients in the 10 mg group) 
underwent hemodynamic testing at baseline and after com-
pleting 12 weeks of therapy. In the combined analysis of all 
dose groups, cardiac index increased (0.33 ± 0.47 L/min/m2), 
and mean pulmonary arterial pressure and pulmonary 
vascular resistance decreased compared with baseline 
(–5.2 ± 6.2 mm Hg and –226 ± 202 dyne.cm/sec2, respec-
tively, p   0.05 for both). Overall, ambrisentan was well 
tolerated. Only 2 out of 64 patients developed elevation in 
LFTs   3 times the upper limit of normal during the ﬁ  rst 
24 weeks of therapy. Patients who completed the 24-week 
study were eligible to participate in a long-term, open-label 
extension study. Fifty-four patients continued treatment and 
50 of these patients were receiving ambrisentan monotherapy 
after 48 weeks of treatment. A combined analysis of the 
overall patient population demonstrated that the clinical 
beneﬁ  ts of ambrisentan were sustained over the 1-year study 
period, including improvements in 6MWD (mean increase 
55 ± 55 m, p   0.0001 for all dose groups combined), BDI, 
and WHO functional class (Galie et al 2005b).
After the initial dose ranging study, 2 Phase III trials with 
ambrisentan were initiated (Galie et al 2008). Both trials were 
named ARIES (AmbRISentan in patients with moderate 
to severe PAH) and were randomized, placebo controlled, 
double blinded investigations with an identical design except 
for the dose of ambrisentan. In ARIES-1, patients from the 
US and Australia with idiopathic PAH or PAH associated 
with connective tissue disease, HIV infection or anorectic 
drug use were randomized to 5 mg or 10 mg ambrisentan 
daily or placebo. The same entry criteria were used for the 
ARIES-2 study in Europe, Africa and South America, but 
patients were randomized to 2.5 or 5 mg of ambrisentan or 
placebo.
All randomized patients received at least 1 dose of study 
drug, except for 1 patient in the 10-mg group of ARIES-1 
who was not included in the analysis of safety or efﬁ  cacy. An 
increase in 6MWD was observed in each ambrisentan dose 
group at week 4, and this effect was maintained at weeks 
8 and 12, whereas in the placebo group, it deteriorated by 
week 12 (Figure 2). The mean placebo-corrected treatment 
effects at week 12 were 31 m (95% conﬁ  dence interval [CI], 
3 to 59; p = 0.008) for ambrisentan 5 mg and 51 m (95% CI, 
27 to 76; p   0.001) for ambrisentan 10 mg in ARIES-1; 32 m 
(95% CI, 2 to 63; p = 0.022) for ambrisentan 2.5 mg and 
59 m (95% CI, 30 to 89; p   0.001) for ambrisentan 5 mg 
in ARIES-2; and 45 m (95% CI, 24 to 65; p   0.001) for 
the combined 5-mg group from both studies. In both stud-
ies, improvements in the mean placebo-corrected 6MWD 
were observed at week 12 in patients with baseline WHO 
functional class II (range, 36 to 55 m) and WHO functional 
class III (range, 39 to 45 m). Similarly, improvements in 
placebo corrected 6 MWD were observed in both idiopathic 
PAH patients (range, 50 to 66 m) and, to a lesser extent, for 
patients with PAH associated with connective tissue disease 
(range, 15 to 23 m).
In ARIES-2, patients treated with ambrisentan had a 
longer time before clinical worsening, a composite endpoint 
deﬁ  ned as death, hospitalization for PAH, lung transplanta-
tion, atrial septostomy, withdrawal from the study to initi-
ate therapy with other PAH medications, or early escape 
criteria (Figure 3) (p   0.001 for both ambrisentan doses 
combined versus placebo). Similar results were observed 
for the 2.5- and 5-mg ambrisentan groups separately 
(p = 0.005, P = 0.008). Time to clinical worsening was not 
signiﬁ  cantly different in ambrisentan and placebo treated 
patients in ARIES-1 (p = 0.307, p = 0.292, and p = 0.214, 
for the 5-mg group, 10-mg group, and combined groups, 
respectively). However, the rate of clinical worsening for 
the placebo groups was considerably lower in ARIES-1 than 
in ARIES-2 (9% versus 22%) and the lack of difference 
in rates of worsening between placebo and ambrisentan 
treated patients in ARIES-1 was due more to the lower rate 
of deterioration in the placebo group than to a higher rate of 
worsening in the ambrisentan treated group. In fact, the rates 
of clinical worsening for patients treated with ambrisentan 
were nearly identical in ARIES-1 and -2 (4% versus 5%, 
respectively) and a statistically signiﬁ  cant improvement in 
time to clinical worsening was observed for the combined 
5-mg groups compared with the combined placebo groups 
from both studies (p = 0.005).
In ARIES-1 and -2, WHO functional class decreased 
more in the placebo treated group than in the ambrisentan 
groups, however, the difference was statistically signiﬁ  cant 
only in ARIES-1 (p = 0.036 and p = 0.117, for ARIES-1 
and ARIES-2, respectively) For ARIES-1 and -2, WHO 
class in the combined 5-mg group improved from baseline 
to week 12 compared with the combined placebo group Drug Design, Development and Therapy 2008:2 272
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(p = 0.025). In both studies, the treatment effects observed 
were due primarily to less WHO functional class deterioration 
in patients receiving ambrisentan compared with patients 
receiving placebo (ARIES-1, 3.0% and 16.4%, respectively; 
ARIES-2, 3.9% and 18.5%, respectively).
In ARIES-2, the SF-36 Health Survey Physical Function-
ing scale signiﬁ  cantly improved (P = 0.005) in the combined 
ambrisentan group (3.41 ± 6.96) compared with the placebo 
group (−0.20 ± 7.14); improvements in this parameter 
also were noted in the individual 2.5-mg (p = 0.005) and 
5-mg (p = 0.040) dose groups. Furthermore, improvements 
were observed in several other SF-36 scales, including 
Role-Physical, Vitality, Role-Emotional, and General Health. 
In ARIES-1, similar trends were observed without statistical 
signiﬁ  cance (Rubin 2002).
An improvement in BDI was observed at week 12 for 
the combined ambrisentan group compared with placebo 
in ARIES-1 (–0.6; 95% CI, –1.2 to 0.0; p = 0.017) and 
ARIES-2 (–1.1; 95% CI, –1.8 to –0.4; p = 0.019). Improve-
ments in Borg dyspnea score compared with placebo also 
were noted for the 10-mg group in ARIES-1 (–0.9; 95% 
CI, –1.6 to –0.2; p = 0.002), for the 2.5-mg (–1.0; 95% CI, 
–1.9 to –0.2; p  = 0.046) and 5-mg (–1.2; 95% CI, –2.0 to 
–0.4; p = 0.040) groups in ARIES-2, and for the combined 
5-mg group (–0.7; 95% CI, –1.3 to –0.2; p = 0.031) from 
both studies.
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Figure 2 Changes from baseline in the 6-minute walking distance at week 12 in the placebo and ambrisentan groups from the ARIES-1 and ARIES-2 studies. For ARIES-1, 
p = 0.008 and p   0.001 for the 5-mg and 10-mg ambrisentan groups vs placebo, respectively. In ARIES-2, p = 0.022 and p   0.001 for the 2.5-mg and 5-mg ambrisentan 
groups vs placebo, respectively. Values shown are mean ± SE. Reproduced with permission from Galie N, Olschewski H, Oudiz RJ, et al 2008. Ambrisentan for the treatment 
of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efﬁ  cacy (ARIES) 























































Figure 3 Kaplan-Meier estimates of the proportion of patients with clinical worsening in the ARIES-1 and ARIES-2 studies. See text for deﬁ  nition of clinical worsening. In ARIES-1, 
no signiﬁ  cant differences were seen between the ambrisentan 5-mg and 10-mg groups vs placebo or the 5-mg and 10-mg groups combined vs placebo. In ARIES-2, p = 0.005, 
p = 0.008, and p   0.001 for the ambrisentan 2.5-mg, 5-mg, and 2.5 plus 5-mg dose groups combined, respectively. Reproduced with permission from Galie N, Olschewski H, 
Oudiz RJ, et al 2008. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-
blind, placebo-controlled, multicenter, efﬁ  cacy (ARIES) study 1 and 2. Circulation, 117:3010–9. Copyright © 2008. Lippincott Williams & Wilkins.
No assessment of cardiopulmonary hemodynamics was 
made in either ARIES study. However, baseline and 12 week 
treatment levels of B-type natriuretic peptide (BNP) were 
measured. Plasma BNP levels have been shown to correlate 
inversely with survival in PAH. In particular, a baseline BNP 
level of  155 pg/mL has been associated with increased 
mortality as has a failure to decrease BNP   180 pg/mL 
after therapy (Nagaya et al 2000). In both ARIES studies, 
plasma BNP levels were similar at baseline in the placebo and 
ambrisentan groups. At week 12, plasma BNP concentrations 
in the placebo groups increased slightly from baseline by 
9% and 13% (ARIES-1 and ARIES-2, respectively). In 
contrast, plasma BNP levels decreased from baseline in the 
5-mg (30%) and 10-mg (45%) groups in ARIES-1 and in the Drug Design, Development and Therapy 2008:2 274
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2.5-mg (29%) and 5-mg (30%) groups in ARIES-2 (p   0.003 
for each dose group). Mean BNP levels after 12 weeks of 
treatment were   than 100 pg/mL in placebo groups from 
both studies and  100 pg/mL in each of the 4 ambrisentan 
dose groups.
Of the 361 patients who entered into the long-term 
extension study, 43 discontinued before completing 48 weeks 
of treatment. Fourteen of the 43 died. The 43 patients who 
discontinued had more severe disease at baseline, as evidenced 
by a lower baseline 6MWD, a higher baseline BDI, and a worse 
baseline WHO functional class. A total of 298 out of the 318 
patients who remained in the extension study received at least 
48 weeks of ambrisentan therapy. Twenty additional patients 
remained in the study but had received less than 48 weeks of 
therapy at the time data were analyzed (November 30, 2006). 
Eighteen of the 298 patients received additional treatments 
(prostanoids or phosphodiesterase type 5 inhibitors) during the 
extension study. For the 280 patients receiving ambrisentan 
monotherapy for 48 weeks the mean change from baseline in 
6MWD was 40 m (95% CI, 33 to 48 m) at week 12 and 39 m 
(95% CI, 29 to 49 m) at week 48, suggesting that the initial 
improvement in exercise capacity was sustained for nearly 
a year.
Safety
Ambrisentan was generally well tolerated in the few 
clinical studies that have been completed thus far. The 
most frequently reported adverse events during the Phase 2, 
dose-ranging study were peripheral edema, nasal conges-
tion, upper respiratory tract infection, headache, ﬂ  ushing, 
and nausea (Galie et al 2005a). None of these symptoms 
appeared to occur more frequently at higher doses of 
ambrisentan, although the number treated with each dose 
was small. Ambrisentan was well tolerated throughout 
the 1-year extension study, with only 1 patient requiring 
discontinuation due to elevated hepatic aminotransferases. 
In the ARIES-1 and -2 studies, the most common adverse 
effects in patients who received ambrisentan were, again 
peripheral edema, sinusitis, naropharyngitis, nasal congestion 
and ﬂ  ushing (Table 2). Interestingly, peripheral edema, the 
Table 2 Incidence of serum aminotransferase elevation in clinical trials of endothelin receptor antagonists for the treatment of pulmonary 
hypertension




BREATHE-1 Rubin et al 2002 Placebo 69 16 weeks
Bosentan 125 mg bid 74 4
250 mg bid 70 14
STRIDE-1 Barst et al 2004 Placebo 60 12 weeks 3
Sitaxsentan 100 mg qd 55 0
300 mg qd 63 10
26 weeks
Sitaxsentan 100 mg qd 5
300 mg qd 21
STRIDE-2 Barst et al 2006 Placebo 51 18 weeks 6
Sitaxsentan 50 mg qd 54 3
100 mg qd 57 5
Bosentan 125 mg bid 52 11
Ambrisentan Dose 
Ranging Study
Galie et al 2005 1 mg qd 16 24 weeks 0
2.5 mg qd 19 10.5
5 mg qd 16 12. 5
10 mg qd 13 0




LFT – liver function tests, *Elevation of serum hepatic aminotransferase levels greater than 3 times the upper limit of normal.Drug Design, Development and Therapy 2008:2 275
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most common adverse effect reported, occurred more than 
twice as often in patients given ambrisentan than in those 
who received placebo in AIRES-1, (27.6 versus 10.4%) but 
was the same for ambrisentan and placebo treated patients in 
AIRES-2 (6.2 versus 10.8% for ambrisentan versus placebo, 
respectively). During the 12-week study period in ARIES-1 
and -2, there were no signiﬁ  cant changes from baseline in 
prothrombin time or international normalized ratio in the 
ambrisentan- or placebo-treated groups.
Although no study has compared the incidence of liver 
function abnormalities necessitating discontinuation of 
therapy between ambrisentan and other ERAs, the overall 
incidence of serum aminotransferase elevation has been 
somewhat lower with ambrisentan than in similar studies 
with bosentan and sitaxsentan (Table 2). During the Phase 2, 
24-week study, 2 (3%) patients experienced elevations 
in hepatic aminotransferases  3 times the upper limit of 
normal (ULN), that necessitated dose reduction or drug 
discontinuation. Two patients had isolated aminotransferase 
elevations that were unconﬁ  rmed upon retest and required no 
change in treatment. At the start of the long-term extension 
study (ie, after 24 weeks of ambrisentan treatment), 48% of 
patients were receiving the maximal dose of ambrisentan 
(10 mg) and no additional elevations of alanine aminotrans-
ferase (ALT) or aspartate aminotransferase (AST)  3 times 
ULN were observed after one year follow-up. In ARIES-1 
and -2, none of the 261 patients receiving ambrisentan 
developed serum ALT or AST   3 times ULN during the 
ﬁ  rst 12 weeks of therapy compared with 3 patients (2.3%) in 
the placebo groups. Moreover, mean values for, AST, ALT, 
total bilirubin, and alkaline phosphatase did not increase 
from baseline in the ambrisentan groups. These results 
compare favorably to the 4% to 14% incidence of serum 
aminotranferase elevation  3 times ULN in clinical trials 
of bosentan and the 3% to 6% incidence of elevated liver 
function tests reported with sitaxsentan (Table 2) (Rubin 
et al 2002; Barst et al 2004; Barst et al 2006; Provencher 
et al 2006; Benza et al 2008).
The incidence of aminotransferase elevation with 
ambrisentan does not appear to be dose related, whereas 
both bosentan and sitaxsentan demonstrate increased 
hepatotoxicity at higher doses (Table 2). For example, 
the incidence of serum aminotransferase elevation in one 
trial of bosentan was 3 times higher in patients assigned 
to 250 mg bid (14%) than in those receiving the currently 
approved dose of 125 mg bid (4%) for a mean duration of 
129 days (Rubin et al 2002) Likewise, the incidence of LFT 
elevation was 21% and 5% for patients receiving 300 mg 
and 100 mg daily, respectively for up to 58 weeks (median 
26 weeks) (Barst et al 2004).
Recently, results from an open-label Phase 2 study of 
ambrisentan in patients with PAH who had previously dis-
continued bosentan and/or sitaxsentan because of increased 
liver aminotransferase levels were reported (McGoon et al 
2008). Thirty-six patients were evaluated. 31 had discon-
tinued bosentan, 2 had discontinued sitaxsentan, and 3 had 
discontinued both. The median duration of treatment with 
an ERA prior to discontinuation was 9 weeks. None of the 
36 patients enrolled in the study had a recurrence of liver 
function abnormalities that resulted in discontinuation of 
ambrisentan during the initial 12-week evaluation period. 
One patient experienced a transient increase in hepatic 
aminotransferases  3 times ULN that resulted in dose reduc-
tion. No further elevations  3 times ULN were observed 
with ambrisentan exposure after 1 year. Thus, the incidence 
of elevated liver function tests with ambrisentan appears to 
be lower than other ET receptor antagonistswith a pyrimidine 
structure such as bosentan or sitaxsentan. However, it should 
be noted that most of the LFT abnormalities associated with 
sitaxsentan have been seen with the 300-mg daily dose that is 
note approved for treatment. At the presently approved dose 
of 100 mg daily, the incidence of LFT elevation  3 times 
the upper limit or normal appears to be similar in sitaxsentan 
and ambrisentan (Benza et al 2008; Galie et al 2005).
Interestingly, no clinically relevant increase in hepatic 
aminotransferases was reported in the clinical trials with 
darusentan, another diphenyl propionic acid derivatives 
(Luscher et al 2002; Anand et al 2004). It is possible that 
the lower rate of elevated liver function tests associated with 
ambrisentan may be due to its cytochrome p450 independent 
metabolism (Cernacek et al 1998). However, it should be 
recognized that signiﬁ  cant elevations in serum aminotrans-
ferases have been reported with ambrisentan and that all 
patients receiving ambrisentan are required by the FDA to 
have liver function tests monitored monthly for as long as 
they are on therapy.
Decreases in hemoglobin concentration have also been 
recognized as a class effect associated with ERAs (Galie et al 
2005a). In the Phase 2 ambrisentan trial, decreases in hemo-
globin concentrations were observed as early as week 2 and 
remained stable throughout the 12-week study (mean change 
from baseline to week 12 was −0.8 g/dL); however no further 
decreases were observed during the subsequent 12-week, 
open-label treatment period. In ARIES 1 and 2 the mean 
hemoglobin concentration fell by 0.84 ± 1.2 g/dL in patients 
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increase in the placebo group, but the change was not dose 
dependent.
Ambrisentan therapy for PAH
Data from the inital open label dosing study and the 
subsequent 2 concurrent, randomized, double blind, 
placebo-controlled studies demonstrate that ambrisentan 
improves 6MWD in patients with PAH and, at the 5 mg/day 
dose, delays time to clinical worsening. At the same time, 
adverse events were similar to those experienced in clinical 
trials with other ERAs, with the exception of a lower inci-
dence of serum aminotransferase elevation than in clinical 
trials of bosentan or sitaxsentan. Ambrisentan was well 
tolerated in a small number of patients who experienced 
amiontransferase elevation with other ERAs (McGoon et al 
2008), although it is not known whether these patients would 
have experienced repeat elevation in aminotransferase levels 
had they been re-challenged with their original ERA. Despite 
their marked differences in endothelin receptor selectivity, 
clinical responses to all 3 agents have been strikingly similar 
(Bayes et al 2006; Torres 2007). Placebo adjusted improve-
ments in cardiopulmonary hemodynamics,exercise capac-
ity, and functional status have been essentially the same 
with bosentan, sitaxsentan and ambrisentan in short term 
placebo controlled trials and in longer term open label stud-
ies (Table 3). Survial data beyond a year is only available 
for bosentan. Thus, it is not yet known whether selective or 
non-selective ERAs have a greater effect on mortality. The 
question of whether differential blockade of ETA offers any 
advantages in the treatment of PAH would be best answered 
by randomized clinical trials comparing ETA selective and 
non-selective agents. Unforutnately, comparative trials of 
ambrisentan versus other ERAs have not been done. The 
large number of patients needed to detect small differences 
between presently available ERAs may make these studies 
untenable. Thus, it is not possible to determine if there are 
signiﬁ  cant differences in safety or efﬁ  cacy between these 
agents. Until more long-term data with ambrisentan are avail-
able, the beneﬁ  ts of once daily dosing and lower incidence 
of elevated liver function tests should be weighed against 
the greater clinical experience with the other ERAs in the 
treatment of PAH.
It is also important that ambrisentan, like other ERAs be 
utilized in the appropriate clinical setting. In a retrospective 
review of 103 consecutive PAH patients in WHO functional 
class III or IV, Provencher and colleagues found that 44% 
of patients who were started on monotherapy with bosen-
tan required addition of prostanoid therapy within 2 years 
(Provencher et al 2006). Clinical characteristics that predicted 
worse long-term response to bosentan therapy, included 
WHO functional class IV at baseline, failure to improve 
from WHO functional class III after 4 months of treatment, 
a 6MWD shorter than 250 m at baseline, a decrease of more 
than 10% in 6MWD on 2 consecutive tests performed at least 
2 weeks apart, and a cardiac index of less than 2.2 L/min/m 
(Provencher et al 2006). Due to its similar mode of action, it 
is unlikely that patients like these will respond any better to 
other ERAs including ambrisentan. The FDA has approved 
ambrisentan for treatment of WHO functional class II or III 
patients, but not class IV. Treatment guidelines published 
by professional societies also suggest that PAH patients 
in functional class IV at initial evaluation or who progress 
to functional class IV during therapy are not good candidates 
for treatment with ambrisentan alone (Badesch et al 2004). 
Instead, these patients should be treated with prostacyclin 
infusion either alone or in combination with sildenaﬁ  l or an 
ERA. Under these circumstances, ambrisentan would be an 
appropriate adjunct to prostacyclin infusion therapy.
Combination therapy 
with ambrisentan
Potential drug–drug interactions between ambrisentan 
and sildenaﬁ  l or warfarin have been evaluated in healthy 
subjects. Pharmacokinetic parameters of ambrisentan and 
sildenaﬁ  l were similar when administered as monotherapy 
or in combination. The pharmacokinetics of n-desmethyl-
sildenaﬁ  l, the active metabolite of sildenaﬁ  l, were also unaf-
fected by multiple doses of ambrisentan (Dufton et al 2006). 
The interaction of ambrisentan and warfarin was evaluated in 
22 healthy volunteers, who were given a single 25-mg oral 
dose of warfarin before and after 8 days of oral ambrisentan 
10 mg/day (Gerber 2006). Ambrisentan did not affect the 
Cmax or AUC of warfarin, although a small reduction in 
prothrombin time was observed (−14.2%; 95% CI, −16.6% 
to −11.8%). In both studies, ambrisentan was well tolerated 
and no safety concerns arose with the combination therapies. 
The lack of a pharmacodynamic effect of ambrisentan on 
warfarin metabolism has been conﬁ  rmed in ambrisentan 
clinical trials to date.
The recognition that monotherapy for PAH with presently 
available therapies is often inadequate, has led investiga-
tors to consider combining multiple classes of pulmonary 
vasodilators (Humbert et al 2004a). The lack of identiﬁ  able 
adverse interactions between ambrisentan and sildenaﬁ  l 
or prostacyclin make it well suited for future combination 
therapies in PAH.Drug Design, Development and Therapy 2008:2 278
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Conclusion
Ambrisentan appears to be a safe and efﬁ  cacious treatment 
for PAH patients in WHO functional class II or III. At the 
present time, it is unclear if selective ERAs like ambrisentan 
offer any clinical advantages over non-selective ERAs or 
phosphodiesterase inhibitors. Improvements in pulmonary 
hemodynamics and exercise capacity with ambrisentan are 
similar to those achieved with other approved therapies for 
PAH. Ambrisentan does have a lower incidence of serum 
aminotransferase elevation than other ERAs and requires 
only once daily dosing. However, these advantages should 
be weighed against the limited long-term experience with this 
agent in treating PAH. More data are needed on the sustained 
efﬁ  cacy and safety of ambrisentan during prolonged treat-
ment of PAH, and on the effect of extended ambrisentan 
therapy on survival. In the meantime, its favorable efﬁ  cacy 
and safety proﬁ  le demonstrated in Phase II and III clinical 
trials and its ease of use suggest that ambrisentan will play 
an important role in the medical therapy for PAH and pro-
vide another therapeutic options to combat this challenging 
disease.
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